drugset / Trial / NCT00277550

The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia

NCT00277550

Phase 4 Withdrawn Novartis Mayo Clinic · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with CC and upper GI symptoms of dyspepsia

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegaserod Small molecule 6 mg

Indications